TipRanks on MSN
Incyte’s New Study on Axatilimab: A Potential Game-Changer for Pediatric Graft-Versus-Host Disease
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is launching a new clinical study titled ‘A Phase 2, ...
Incyte (($INCY)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a study titled ‘A Prospective, ...
On September 6, Glenn received donor stem cells from a 23-year-old man located through the National Marrow Donor Program.
Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for ...
Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard ...
A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...
Designation places Mount Sinai among top one percent of cancer centers nationwide Mount Sinai Tisch Cancer Hospital Mount ...
Sanofi gained Rezurock in a $1.9 billion buyout of Kadmon in 2021, less than two months after the FDA approved the treatment ...
New research found that gene therapy for children with "bubble boy disease," or SCID, was successful in 95% of trial ...
Picture this: you’re surviving cancer, chemotherapy, radiation, immunosuppression, and a blood stem cell transplant, and you haven’t left the hospital in weeks. Yet, somehow, you have what feels and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback